179. Generic Semaglutide — What We Know, What We Don’t, and What Matters as of May 2026
In this episode, I walk through what’s actually happening with generic semaglutide right now—and what it means for you in real life, not just in headlines.
I explain where semaglutide fits in the bigger picture, how it compares to tirzepatide, and why generics are entering the market now. I also break down what “bioequivalence” really means—and why that nuance matters when it comes to effectiveness and side effects.
I talk about early pricing estimates, what we might see happen with brand-name costs, and how pharmacy-level substitution could impact what patients are actually given. We get into the practical questions I’m already hearing: what the devices will look like, whether dosing will feel the same, and how switching between products might affect different patients.
I also share how I’m thinking about this clinically—who will likely transition easily, and who may need a more cautious, individualized approach. And importantly, I address a growing issue: access to medication is not the same as access to care. Obesity treatment is more than a prescription—it’s ongoing, structured medical care.
Bottom line: I’m genuinely encouraged by the potential for improved access—but your treatment should still be guided by your individual response, not just what’s available.
This is an evolving space, and I’ll keep you updated as we learn more.
WORK WITH ME
Ontario-Wide Virtual Obesity Management Clinic https://www.highmetabolicclinic.com
Join my Healthy Lifestyle Coaching Program for women, Best Weight https://www.sashahighmd.com/bestweight
Binge Eating Disorder Treatment - https://www.sashahighmd.com/bed
Taking the first step toward weight loss can feel overwhelming — but you don’t have to do it alone. I’ve created a curated list of my podcast episodes to gently guide you as you begin your journey. https://www.sashahighmd.com/podcast-guide
FOLLOW ME on Instagram - https://www.instagram.com/sashahighmd/
